WallStSmart

Merck & Company Inc (MRK)vsTwist Bioscience Corp (TWST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 15317% more annual revenue ($66.57B vs $431.80M). MRK leads profitability with a 4.8% profit margin vs -31.7%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TWST

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 4/9Altman Z: -0.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$150.91

$67.87 premium

UndervaluedFair: $83.04Overvalued
TWSTUndervalued (+57.1%)

Margin of Safety

+57.1%

Fair Value

$115.60

Current Price

$164.60

$49.00 discount

UndervaluedFair: $115.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

TWST2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
23.2%8/10

Revenue surging 23.2% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

TWST4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
23.2x2/10

Trading at 23.2x book value

Return on EquityProfitability
-17.9%2/10

ROE of -17.9% — below average capital efficiency

Free Cash FlowQuality
$-8.55M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : TWST

The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : TWST

The primary concerns for TWST are EPS Growth, Price/Book, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while TWST is a growth play — different risk/reward profiles.

TWST carries more volatility with a beta of 2.22 — expect wider price swings.

TWST is growing revenue faster at 23.2% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 29/100). TWST offers better value entry with a 57.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Twist Bioscience Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?